AXSM Quote, Financials, Valuation and Earnings

Fortress Biotech, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 50.07%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Fortress Biotech, Inc.'s return on equity of -223.06%.

Axsome Therapeutics, Inc. has a consensus price target of $181.59, signalling upside risk potential of 19.43%. On the other hand Fortress Biotech, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 187.43%. Given that Fortress Biotech, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc. has a beta of 0.476, which suggesting that the stock is 52.416% less volatile than S&P 500. In comparison Fortress Biotech, Inc. has a beta of 1.490, suggesting its more volatile than the S&P 500 by 49.031%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Fortress Biotech, Inc. pays out 3.9% of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are larger than Fortress Biotech, Inc. quarterly revenues of $17.6M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Fortress Biotech, Inc.'s net income of $8.8M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Fortress Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 13.33x versus 1.76x for Fortress Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 39.21%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Axsome Therapeutics, Inc. has a consensus price target of $181.59, signalling upside risk potential of 19.43%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 6.16%. Given that Axsome Therapeutics, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Axsome Therapeutics, Inc. is more attractive than Gilead Sciences, Inc..

Axsome Therapeutics, Inc. has a beta of 0.476, which suggesting that the stock is 52.416% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.53% to investors and pays a quarterly dividend of $0.79 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 19.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 13.33x versus 5.39x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Karyopharm Therapeutics, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of -75.21%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Karyopharm Therapeutics, Inc.'s return on equity of --.

Axsome Therapeutics, Inc. has a consensus price target of $181.59, signalling upside risk potential of 19.43%. On the other hand Karyopharm Therapeutics, Inc. has an analysts' consensus of $14.67 which suggests that it could grow by 97.13%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc. has a beta of 0.476, which suggesting that the stock is 52.416% less volatile than S&P 500. In comparison Karyopharm Therapeutics, Inc. has a beta of 0.228, suggesting its less volatile than the S&P 500 by 77.201%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Karyopharm Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Karyopharm Therapeutics, Inc. pays out -- of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are larger than Karyopharm Therapeutics, Inc. quarterly revenues of $44M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Karyopharm Therapeutics, Inc.'s net income of -$33.1M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Karyopharm Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 13.33x versus 0.45x for Karyopharm Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 19.97%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat TG Therapeutics, Inc.'s return on equity of 145.71%.

Axsome Therapeutics, Inc. has a consensus price target of $181.59, signalling upside risk potential of 19.43%. On the other hand TG Therapeutics, Inc. has an analysts' consensus of $44.29 which suggests that it could grow by 43.93%. Given that TG Therapeutics, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc. has a beta of 0.476, which suggesting that the stock is 52.416% less volatile than S&P 500. In comparison TG Therapeutics, Inc. has a beta of 2.014, suggesting its more volatile than the S&P 500 by 101.386%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. TG Therapeutics, Inc. pays out -- of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are larger than TG Therapeutics, Inc. quarterly revenues of $161.7M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than TG Therapeutics, Inc.'s net income of $390.9M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while TG Therapeutics, Inc.'s PE ratio is 11.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 13.33x versus 9.35x for TG Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.